Sanofi pays Regeneron $1 billion upfront to expand immunology alliance
Sanofi and Regeneron expanded their immunology partnership to develop four next-generation, long-acting antibodies targeting type 2 inflammation, including one already in Phase 1 testing. Sanofi will pay Regeneron $1 billion upfront, with up to $7 billion in milestone payments; the companies will share development costs and future profits equally, while leaving Dupixent’s existing economics unchanged.
Business · 24 sources · 1dRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Sanofi
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000.
Everything about Sanofi →- Country
- France
- Headquarters
- Paris
- Inception
- August 20, 2004
- Website
- https://www.sanofi.com/, https://www.sanofi.us/